Literature DB >> 22576064

Characteristics and outcomes of sentinel node-positive breast cancer patients after total mastectomy without axillary-specific treatment.

Sarah Milgrom1, Hiram Cody, Lee Tan, Monica Morrow, Catherine Pesce, Jeremy Setton, Katherine Rogers, Brittany Arnold, Anne Eaton, Jeffrey Catalano, Beryl McCormick, Simon Powell, Alice Ho.   

Abstract

PURPOSE: Regional failure rates are low in patients with a positive sentinel lymph node biopsy (SLNB) who undergo breast-conserving therapy without axillary lymph node dissection (ALND). The applicability of these findings to total mastectomy (TM) patients is not established. Our aims were to evaluate the characteristics and outcomes of SLNB-positive TM patients who did not receive axillary-specific treatment and to compare them to similar patients who underwent breast-conserving surgery (BCS).
METHODS: A total of 535 patients with early-stage breast cancer who underwent definitive breast surgery (210 TM, 325 BCS), had a positive SLNB and did not receive ALND between 1997 and 2009 were identified from an institutional database. Characteristics and outcomes were compared between the TM and BCS groups.
RESULTS: Most patients had stage I to IIA, estrogen receptor-positive, progesterone receptor-positive, Her2-negative invasive ductal carcinoma, with minimal nodal disease. Compared to the BCS group, TM patients were younger, had larger tumors, had higher nomogram scores predicting additional axillary disease and were more likely to receive chemotherapy. Ninety-four percent of the BCS cohort and 5 % of the TM cohort received adjuvant radiotherapy. At a median follow-up of 57.8 months, the 4-year local, regional and distant failure rates were 1.7, 1.2 and 0.7 % in the TM group and 1.4, 1.0 and 3.7 % in the BCS group. The 4-year disease-free and overall survival rates were 94.8 and 97.8 % in the TM group and 90.1 and 92.6 % in the BCS group.
CONCLUSIONS: Early-stage breast cancer patients with minimal sentinel node disease experience excellent outcomes without ALND, whether they undergo BCS or TM.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22576064     DOI: 10.1245/s10434-012-2386-3

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  13 in total

1.  Axillary Micrometastases and Isolated Tumor Cells Are Not an Indication for Post-mastectomy Radiotherapy in Stage 1 and 2 Breast Cancer.

Authors:  Anita Mamtani; Sujata Patil; Michelle Stempel; Monica Morrow
Journal:  Ann Surg Oncol       Date:  2017-04-20       Impact factor: 5.344

2.  Disease recurrence in sentinel node-positive breast cancer patients forgoing axillary lymph node dissection.

Authors:  Amy Cyr; Feng Gao; William E Gillanders; Rebecca L Aft; Timothy J Eberlein; Julie A Margenthaler
Journal:  Ann Surg Oncol       Date:  2012-08-14       Impact factor: 5.344

3.  Axilla lymph node dissection can be safely omitted in patients with 1-2 positive sentinel nodes receiving mastectomy: a large multi-institutional study and a systemic meta-analysis.

Authors:  Weiqi Gao; Shuangshuang Lu; Yufei Zeng; Xiaosong Chen; Kunwei Shen
Journal:  Breast Cancer Res Treat       Date:  2022-09-08       Impact factor: 4.624

4.  Outcomes of Sentinel Lymph Node-Positive Breast Cancer Patients Treated with Mastectomy Without Axillary Therapy.

Authors:  Elizabeth FitzSullivan; Roland L Bassett; Henry M Kuerer; Elizabeth A Mittendorf; Min Yi; Kelly K Hunt; Gildy V Babiera; Abigail S Caudle; Dalliah M Black; Isabelle Bedrosian; Chantal Reyna; Mediget Teshome; Funda Meric-Bernstam; Rosa Hwang
Journal:  Ann Surg Oncol       Date:  2016-10-03       Impact factor: 5.344

Review 5.  Local treatment of the axilla in early breast cancer: concepts from the national surgical adjuvant breast and bowel project B-04 to the planned intergroup sentinel mamma trial.

Authors:  Toralf Reimer; Steffi Hartmann; Angrit Stachs; Bernd Gerber
Journal:  Breast Care (Basel)       Date:  2014-05       Impact factor: 2.860

6.  A simple risk score to predict the presence of non-sentinel lymph node metastases in breast cancer patients with a positive sentinel node.

Authors:  Raquel F D van la Parra; Petronella G M Peer; Wilfred K de Roos; Miranda F Ernst; Johannes H W de Wilt; Koop Bosscha
Journal:  World J Surg       Date:  2014-05       Impact factor: 3.352

7.  Successful Completion of the Pilot Phase of a Randomized Controlled Trial Comparing Sentinel Lymph Node Biopsy to No Further Axillary Staging in Patients with Clinical T1-T2 N0 Breast Cancer and Normal Axillary Ultrasound.

Authors:  Amy E Cyr; Natalia Tucker; Foluso Ademuyiwa; Julie A Margenthaler; Rebecca L Aft; Timothy J Eberlein; Catherine M Appleton; Imran Zoberi; Maria A Thomas; Feng Gao; William E Gillanders
Journal:  J Am Coll Surg       Date:  2016-05-20       Impact factor: 6.113

Review 8.  Future directions for monitoring treatment responses in breast cancer.

Authors:  Matthew P Shupe; Lindsey J Graham; Erika J Schneble; Frederick L Flynt; Michael N Clemenshaw; Aaron D Kirkpatrick; Alexander Stojadinovic; George E Peoples; Nathan M Shumway
Journal:  J Cancer       Date:  2014-01-05       Impact factor: 4.207

Review 9.  Mapping lymph nodes in cancer management - role of (99m)Tc-tilmanocept injection.

Authors:  Christoph Tausch; Astrid Baege; Christoph Rageth
Journal:  Onco Targets Ther       Date:  2014-06-24       Impact factor: 4.147

10.  Development of nomograms to predict axillary lymph node status in breast cancer patients.

Authors:  Kai Chen; Jieqiong Liu; Shunrong Li; Lisa Jacobs
Journal:  BMC Cancer       Date:  2017-08-23       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.